Cairo Pharmaceuticals results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit38.8 millionEGP · +23.9% vs the same period a year earlier
Total assets1.33 billionEGP · +18.5% vs the same period a year earlier
Shareholders' equity732 millionEGP · +10.1% vs the same period a year earlier
Operating cash flow-59.02 millionEGP · −294.5% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q1 2023 was about 38.8 million EGP, up +23.9% from 31.3 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 1.33 billion EGP, and shareholders' equity about 732 million EGP.
- Operating cash flow for Q1 2023 was negative at 59.02 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit38.8 million31.3 million+23.9%
Gross profit84.73 million71.46 million+18.6%
Total assets1.33 billion1.12 billion+18.5%
Total liabilities598 million457 million+30.9%
Shareholders' equity732 million665 million+10.1%
Total liabilities and equity1.33 billion1.12 billion+18.5%
Operating cash flow-59.02 million30.35 million−294.5%
Investing cash flow-1.5 million14.86 million−110.1%
Financing cash flow29.22 million——
Net change in cash-31.3 million45.21 million−169.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy